|
Q3 FY2016
As of Feb 29, 2016
|
Q2 FY2016
As of Nov 30, 2015
|
Q1 FY2016
As of Aug 31, 2015
|
Q4 FY2015
As of May 31, 2015
|
Q3 FY2015
As of Feb 28, 2015
|
Q2 FY2015
As of Nov 30, 2014
|
Q1 FY2015
As of Aug 31, 2014
|
Q4 FY2014
As of May 31, 2014
|
Q3 FY2014
As of Feb 28, 2014
|
Q2 FY2014
As of Nov 30, 2013
|
Q1 FY2014
As of Aug 31, 2013
|
Q4 FY2013
As of May 31, 2013
|
Q4 FY2013
As of Apr 23, 2013
|
Q1 FY2013
As of Aug 31, 2012
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||
| CURRENT ASSETS | ||||||||||||||
| Cash and cash equivalents | ||||||||||||||
| Loan receivable from consultant | ||||||||||||||
| Prepaid expenses | ||||||||||||||
| Unamortized fee | ||||||||||||||
| TOTAL CURRENT ASSETS | ||||||||||||||
| INVESTMENTS | ||||||||||||||
| XSE license, net | ||||||||||||||
| Deferred financing | ||||||||||||||
| Patents, net of accumulated amortization of $21,105 and $13,605, respectively | ||||||||||||||
| Licenses, net of accumulated amortization of $305,418 and $268,338 respectively | ||||||||||||||
| TOTAL OTHER ASSETS | ||||||||||||||
| TOTAL ASSETS | ||||||||||||||
| LIABILITIES AND STOCKHOLDERS' (DEFICIT) | ||||||||||||||
| CURRENT LIABILITIES | ||||||||||||||
| Bank overdraft | ||||||||||||||
| Amounts payable to Bank | ||||||||||||||
| Note payable to bank | ||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||
| Notes payable | ||||||||||||||
| Accrued Interest Payable | ||||||||||||||
| Amounts due under Licensing Agreement with Wazzamba SA | ||||||||||||||
| Loans payable to consultants and stockholders | ||||||||||||||
| Convertible notes payable (net of unamortized discounts of $7 and $674,886 respectively) | ||||||||||||||
| Derivative liability for convertible notes payable | ||||||||||||||
| TOTAL CURRENT LIABILITIES AND TOTAL LIABILITIES | ||||||||||||||
| TOTAL CURRENT LIABILITIES AND TOTAL LIABILITIES | ||||||||||||||
| Due to affiliates and shareholders | ||||||||||||||
| TOTAL LONG-TERM LIABILITIES | ||||||||||||||
| STOCKHOLDERS' DEFICIT | ||||||||||||||
| Preferred stock, $0.001 par value, authorized 10,000,000 shares: Series A convertible preferred stock - issued and outstanding 50,000 shares as of February 29, 2016 and May 31, 2015 | ||||||||||||||
| Preferred stock, $0.001 par value, authorized 2,000,000 shares: Series B convertible preferred stock - issued and outstanding 1,950,000 shares as of February 29, 2016 and "0" as of May 31, 2015 | ||||||||||||||
| Common stock, $0.001 par value, authorized 30,000,000 shares: 8,765,022 and 8,805,932,169 shares issued, and 8,765,022 and 8,681,112,367 shares outstanding, as of February 29, 2016 and May 31, 2015 | ||||||||||||||
| Less: Treasury stock 20,803 shares as of February 29, 2016 and 124,819,802 as of May 31, 2015 | ||||||||||||||
| Common stock payable | ||||||||||||||
| Additional paid-in capital | ||||||||||||||
| Preferred series B stock | ||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||
| Accumulated deficit | ||||||||||||||
| Accumulated deficit during development stage | ||||||||||||||
| TOTAL STOCKHOLDERS' DEFICIT | ||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||||||||
Loading...
